Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
Hunt Globally: Deep Research AI Agents for Drug Asset Scouting in Investing, Business Development, and Search & Evaluation
arXiv:2602.15019v1 Announce Type: new Abstract: Bio-pharmaceutical innovation has shifted: many new drug assets now originate outside the United States and are disclosed primarily via regional, non-English channels. Recent data suggests >85% of patent filings originate outside the U.S., with China accounting for nearly half of the global total; a growing share of scholarly output is also non-U.S. Industry estimates put China at ~30% of global drug development, spanning 1,200+ novel candidate
-
cs.AI, q-bio.NC updates on arXiv.org
-
MedScope: Incentivizing "Think with Videos" for Clinical Reasoning via Coarse-to-Fine Tool Calling
arXiv:2602.13332v1 Announce Type: cross Abstract: Long-form clinical videos are central to visual evidence-based decision-making, with growing importance for applications such as surgical robotics and related settings. However, current multimodal large language models typically process videos with passive sampling or weakly grounded inspection, which limits their ability to iteratively locate, verify, and justify predictions with temporally targeted evidence. To close this gap, we propose MedSc
MedScope: Incentivizing "Think with Videos" for Clinical Reasoning via Coarse-to-Fine Tool Calling
-
npj Digital Medicine
-
Empowering genetic discoveries and cardiovascular risk assessment by predicting electrocardiograms from genotype
npj Digital Medicine, Published online: 17 February 2026; doi:10.1038/s41746-026-02438-3Empowering genetic discoveries and cardiovascular risk assessment by predicting electrocardiograms from genotype
Empowering genetic discoveries and cardiovascular risk assessment by predicting electrocardiograms from genotype
npj Digital Medicine, Published online: 17 February 2026; doi:10.1038/s41746-026-02438-3
Empowering genetic discoveries and cardiovascular risk assessment by predicting electrocardiograms from genotype-
npj Digital Medicine
-
Randomized-controlled trial of skills-based vr vs. distraction vr vs. sham VR for chronic low back pain
npj Digital Medicine, Published online: 16 February 2026; doi:10.1038/s41746-026-02437-4Randomized-controlled trial of skills-based vr vs. distraction vr vs. sham VR for chronic low back pain
Randomized-controlled trial of skills-based vr vs. distraction vr vs. sham VR for chronic low back pain
npj Digital Medicine, Published online: 16 February 2026; doi:10.1038/s41746-026-02437-4
Randomized-controlled trial of skills-based vr vs. distraction vr vs. sham VR for chronic low back pain-
(Multiomics OR Omics) AND (Pancreatic)
-
Rare, Yet Targetable: New Perspectives on Ampullary Carcinomas
Int J Mol Sci. 2026 Feb 6;27(3):1597. doi: 10.3390/ijms27031597.ABSTRACTAmpullary carcinoma (AC) is a rare gastrointestinal malignancy with dual intestinal and pancreatobiliary differentiation, complicating diagnosis, staging, and treatment. This review synthesizes current epidemiology, pathology, and multi-omic data to outline a pragmatic care pathway: lineage-first at presentation, mutation-fast at progression. Histology remains the primary classifier: the intestinal subtype generally aligns w
Rare, Yet Targetable: New Perspectives on Ampullary Carcinomas
Int J Mol Sci. 2026 Feb 6;27(3):1597. doi: 10.3390/ijms27031597.
ABSTRACT
Ampullary carcinoma (AC) is a rare gastrointestinal malignancy with dual intestinal and pancreatobiliary differentiation, complicating diagnosis, staging, and treatment. This review synthesizes current epidemiology, pathology, and multi-omic data to outline a pragmatic care pathway: lineage-first at presentation, mutation-fast at progression. Histology remains the primary classifier: the intestinal subtype generally aligns with colorectal regimens, whereas pancreatobiliary and mixed subtypes favor pancreaticobiliary therapy. In selected fit patients, modified FOLFIRINOX may address mixed phenotypes. Next-generation sequencing adds precision by identifying therapeutically relevant alterations, including ERBB2/HER2 amplifications, MSI-high/dMMR, BRAF V600E, and rare NTRK or RET fusions, while KRAS mutations are enriched in pancreatobiliary tumors. We recommend early application of a rapid-core panel (KRAS/BRAF, MSI/dMMR, ERBB2/HER2, RNA-based fusions) to capture high-impact targets, followed by comprehensive profiling at first progression. Liquid biopsy, plasma circulating tumor DNA (ctDNA), or bile-derived DNA may complement tissue and help identify the dominant lineage. Research priorities include ampulla-enriched umbrella trials, explicit AC subcohorts in tissue-agnostic studies, and ctDNA-informed endpoints. This lineage-first, mutation-fast paradigm supports precision care and evidence generation in AC.
PMID:41684016 | PMC:PMC12897727 | DOI:10.3390/ijms27031597
-
InfoQ

-
OpenAI Scales Single Primary Postgresql to Millions of Queries per Second for ChatGPT
OpenAI described how it scaled PostgreSQL to support ChatGPT and its API platform, handling millions of queries per second for hundreds of millions of users. By running a single-primary PostgreSQL deployment on Azure with nearly 50 read replicas, optimizing query patterns, and offloading write-heavy workloads to sharded systems, OpenAI maintained low-latency reads while managing write pressure. By Leela Kumili
OpenAI Scales Single Primary Postgresql to Millions of Queries per Second for ChatGPT
OpenAI described how it scaled PostgreSQL to support ChatGPT and its API platform, handling millions of queries per second for hundreds of millions of users. By running a single-primary PostgreSQL deployment on Azure with nearly 50 read replicas, optimizing query patterns, and offloading write-heavy workloads to sharded systems, OpenAI maintained low-latency reads while managing write pressure.
By Leela Kumili-
STAT

-
STAT+: Researchers take another look at Apple’s hypertension feature
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Good morning health tech readers! Today, we’ve got a ton of updates including news about venture capital funding, telehealth policy, the government’s progress on information blocking, and research into the accuracy of Apple’s new hypertension feature.Continue to STAT+ to read the full story…
STAT+: Researchers take another look at Apple’s hypertension feature
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.
Good morning health tech readers!
Today, we’ve got a ton of updates including news about venture capital funding, telehealth policy, the government’s progress on information blocking, and research into the accuracy of Apple’s new hypertension feature.
Continue to STAT+ to read the full story…


© Business Wire via AP
-
Nature - Issue - nature.com science feeds
-
Self-powered vibration sensor for wearable health care and voice detection
Nature, Published online: 12 February 2026; doi:10.1038/d41586-026-00250-3Densely packed arrays of electrical components called capacitors can form a high-fidelity vibration sensor that can be worn on the skin.
Self-powered vibration sensor for wearable health care and voice detection
Nature, Published online: 12 February 2026; doi:10.1038/d41586-026-00250-3
Densely packed arrays of electrical components called capacitors can form a high-fidelity vibration sensor that can be worn on the skin.-
(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
-
Upconversion mesoporous silica nanoparticles co-delivering celecoxib and rose bengal enable multimodal immunogenic and anti-angiogenic therapy for spinal metastasis of non-small cell lung cancer
Oncogene. 2026 Feb 11. doi: 10.1038/s41388-026-03679-y. Online ahead of print.ABSTRACTNon-small cell lung cancer (NSCLC) with spinal metastasis represents a clinical challenge due to its aggressive nature, limited treatment options, and profound impact on patient quality of life. Here, we report the development of an innovative upconversion mesoporous silica nanoparticle (UCMS) platform co-loaded with celecoxib and rose bengal (UCMS@CXB/RB), engineered to synergistically combine photodynamic the
Upconversion mesoporous silica nanoparticles co-delivering celecoxib and rose bengal enable multimodal immunogenic and anti-angiogenic therapy for spinal metastasis of non-small cell lung cancer
Oncogene. 2026 Feb 11. doi: 10.1038/s41388-026-03679-y. Online ahead of print.
ABSTRACT
Non-small cell lung cancer (NSCLC) with spinal metastasis represents a clinical challenge due to its aggressive nature, limited treatment options, and profound impact on patient quality of life. Here, we report the development of an innovative upconversion mesoporous silica nanoparticle (UCMS) platform co-loaded with celecoxib and rose bengal (UCMS@CXB/RB), engineered to synergistically combine photodynamic therapy (PDT) and cyclooxygenase-2 (COX-2) inhibition. Upon near-infrared (NIR) irradiation, UCMS@CXB/RB generated abundant reactive oxygen species, triggered immunogenic cell death, and significantly suppressed prostaglandin E2 signaling, leading to reduced angiogenesis and improved antitumor immunity. In vitro and in vivo studies confirmed that this nanoplatform effectively remodeled the tumor microenvironment, inhibited tumor growth, and alleviated cancer-induced spinal dysfunction. Single-cell multi-omics analysis further revealed dynamic crosstalk among immune cells, tumor cells, and endothelial populations, providing mechanistic insights into the multifaceted therapeutic effects of UCMS@CXB/RB. Our results underscore the clinical potential of integrating PDT with targeted COX-2 blockade to address the complex pathophysiology of NSCLC spinal metastasis. This study presents a promising minimally invasive therapeutic strategy with strong translational relevance for managing metastatic NSCLC and improving patient outcomes.
PMID:41673094 | DOI:10.1038/s41388-026-03679-y
-
STAT

-
STAT+: Pharmalittle: We’re reading about FDA rejecting a Moderna vaccine, compounding in the crosshairs and more
Hello, everyone, and welcome to the middle of the week. Congratulations on making it this far. It is an accomplishment, after all. The next step is to… keep going. And why not? Just consider the alternatives. On that optimistic note, please join us for a needed cup or three of stimulation. Our choice today is coconut rum. Meanwhile, here are some items of interest to get you going. Have a wonderful day and do drop us a line when you hear something juicy … The U.S. Food and Drug Administration
STAT+: Pharmalittle: We’re reading about FDA rejecting a Moderna vaccine, compounding in the crosshairs and more
Hello, everyone, and welcome to the middle of the week. Congratulations on making it this far. It is an accomplishment, after all. The next step is to… keep going. And why not? Just consider the alternatives. On that optimistic note, please join us for a needed cup or three of stimulation. Our choice today is coconut rum. Meanwhile, here are some items of interest to get you going. Have a wonderful day and do drop us a line when you hear something juicy …
The U.S. Food and Drug Administration refused to review Moderna’s application for a new influenza vaccine, a surprise decision that could raise concerns about the agency’s posture toward drug companies and the Trump administration’s policies on vaccines, STAT writes. Moderna, revealing the rejection, took the unusual step of releasing the letter it had received from Vinay Prasad, who heads the FDA’s biologics division. They also issued a strongly worded statement from its chief executive officer Stephane Bancel, who said the decision “does not further our shared goal of enhancing America’s leadership in developing innovative medicines.” At the heart of the dispute is what existing influenza vaccine Moderna should have used as a control when testing the efficacy of its new shot, which utilizes the same mRNA technology the company used in its Covid-19 vaccine.
The recent moves by the Trump administration against Hims & Hers might only be the start of a crackdown on compounding, STAT explains. In recent days, the Food and Drug Administration issued a warning, the Department of Health & Human Services asked the Department of Justice to open an investigation and, meanwhile, Novo Nordisk filed a patent infringement lawsuit against the company. But while compounded weight-loss drugs proliferated during recent shortages and continued to remain available, the flurry of developments underscores growing unease among regulators with mass-marketed compounded drugs sold by national, vertically integrated telehealth platforms. The FDA has so far focused publicly on misleading marketing, but signs that it may scrutinize compounding practices themselves have the industry on edge, given how many telehealth companies rely on compounded versions of everything from acne treatments to libido drugs.
Continue to STAT+ to read the full story…


© Alex Hogan/STAT
-
npj Digital Medicine
-
Advancing healthcare AI governance through a comprehensive maturity model based on systematic review
npj Digital Medicine, Published online: 11 February 2026; doi:10.1038/s41746-026-02418-7Advancing healthcare AI governance through a comprehensive maturity model based on systematic review
Advancing healthcare AI governance through a comprehensive maturity model based on systematic review
npj Digital Medicine, Published online: 11 February 2026; doi:10.1038/s41746-026-02418-7
Advancing healthcare AI governance through a comprehensive maturity model based on systematic review-
Omics In Lung
-
Spatial and multi-omics transcriptomic dissects platinum resistance in lung adenocarcinoma: a five-gene predictive model with tumor microenvironment dynamics
Chem Biol Interact. 2026 Feb 7:111952. doi: 10.1016/j.cbi.2026.111952. Online ahead of print.ABSTRACTThe scarcity of reliable biomarkers and predictive models for platinum resistance in lung adenocarcinoma (LUAD) poses a significant clinical challenge. This study endeavors to identify molecular subtypes related to platinum resistance and construct a robust predictive model through multi-omics techniques. We performed integrative analysis of public datasets using advanced bioinformatics strategie
Spatial and multi-omics transcriptomic dissects platinum resistance in lung adenocarcinoma: a five-gene predictive model with tumor microenvironment dynamics
Chem Biol Interact. 2026 Feb 7:111952. doi: 10.1016/j.cbi.2026.111952. Online ahead of print.
ABSTRACT
The scarcity of reliable biomarkers and predictive models for platinum resistance in lung adenocarcinoma (LUAD) poses a significant clinical challenge. This study endeavors to identify molecular subtypes related to platinum resistance and construct a robust predictive model through multi-omics techniques. We performed integrative analysis of public datasets using advanced bioinformatics strategies, including spatial transcriptome deconvolution and consensus clustering. Bulk RNA deconvolution analysis was conducted to characterize tumor microenvironment heterogeneity. Feature selection was performed using the Supervised Principal Component (SuperPC) algorithm, followed by diagnostic model construction validated through receiver operating characteristic (ROC) analysis. Functional validation was performed through cytological experiments measuring cisplatin IC50 alterations following gene manipulation in LUAD cell lines. Consensus clustering revealed distinct LUAD subtypes, with Cluster1 demonstrating significant platinum resistance. We first subtyped the patients in the bulk transcriptome data based on consistency clustering, and then analyzed the differences between different platinum-resistant subtypes (Cluster 1 and Cluster 2), so as to screen 333 isotype-specific differentially expressed genes and 15 platinum resistance-related (PRR) genes were selected through machine learning. A refined 5-gene signature (ANKRD29/CACNA2D2/DSP/HSD17B6/SPP1) achieved exceptional predictive performance (AUC=0.9639). Spatial transcriptomics demonstrated compartmentalized expression patterns: SPP1/DSP localized to tumor niches, HSD17B6/CACNA2D2 to epithelial regions, and ANKRD29 depletion in stromal areas. Cellular colocalization analysis revealed malignant epithelial PH proximity to myeloid and mast cells. Functional validation confirmed that ANKRD29/CACNA2D2 overexpression sensitized A549/DDP cells to cisplatin, while DSP/SPP1/HSD17B6 overexpression induced resistance. Experiments in nude mice have shown that these genes are closely related to cisplatin resistance in LUAD. This study identifies the Cluster1 subtype and malignant epithelial PH as crucial determinants of platinum resistance in LUAD. Our innovative 5-gene predictive model exhibits clinical-grade diagnostic accuracy, and spatial transcriptomic characterization offers mechanistic insights into the dynamics of the tumor microenvironment.
PMID:41662930 | DOI:10.1016/j.cbi.2026.111952
-
Journal of Medical Internet Research
-
Problems and Barriers Regarding the Admission, Financing, and Service Provision of Digital Health Apps: Qualitative Stakeholder Survey
Background: Since their introduction with the Digital Care Act in 2019, DiGA are a part of the German statutory healthcare system. In order to become a DiGA, mHealth apps have to complete a certification process covering both technical and evidence related aspects. After completion, DiGA are added to the DiGA-directory, containing a list of all reimbursable DiGA within German statutory health insurance (SHI). The first apps were added at the end of 2020 with the number steadily increasing. The n
Problems and Barriers Regarding the Admission, Financing, and Service Provision of Digital Health Apps: Qualitative Stakeholder Survey
-
(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
-
Quantifying Individual Health Status from Multi-omics Data by Health State Manifold
Phenomics. 2025 Dec 15;5(5):469-486. doi: 10.1007/s43657-024-00188-4. eCollection 2025 Oct.ABSTRACTQuantifying individual health status from increasingly accumulated omics data is essential for both early prevention and intervention of diseases, which attracts great attention from communities of biology and medicine. Most of the existing approaches mainly classify individuals into different catalogues or classes based on phenotypes and biomarkers. However, an individual's health status from a dy
Quantifying Individual Health Status from Multi-omics Data by Health State Manifold
Phenomics. 2025 Dec 15;5(5):469-486. doi: 10.1007/s43657-024-00188-4. eCollection 2025 Oct.
ABSTRACT
Quantifying individual health status from increasingly accumulated omics data is essential for both early prevention and intervention of diseases, which attracts great attention from communities of biology and medicine. Most of the existing approaches mainly classify individuals into different catalogues or classes based on phenotypes and biomarkers. However, an individual's health status from a dynamical systems viewpoint can be viewed as a non-equilibrium steady state, which can generally be characterized by two key features, i.e. (1) homeostatic potential that represents the ability of homeostatic resilience to withstand perturbations or maintain functions at the current state/phenotype of this individual and (2) phenotypic potential that represents the state/phenotype of the individual on the whole process from health to disease. Here, we proposed a health state manifold (HSM) method derived from dynamic network biomarker method and diffusion map theory to quantify individual health status with the characterization of such two features in a robust and accurate manner based on multi-omics data. To verify our method, HSM method was applied to the quantification of diabetes mellitus (rat subjects) and the Roux-en-Y Gastric Bypass (human subjects) for both disease progression process and recovery process, which demonstrated its effectiveness and potential for personalized medicine and preventive medicine.
SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s43657-024-00188-4.
PMID:41659741 | PMC:PMC12881232 | DOI:10.1007/s43657-024-00188-4
-
(Multiomics OR Omics) AND (Pancreatic)
-
Spatial Multi-omics Analyses Reveal Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation
Cancer Res. 2026 Feb 9. doi: 10.1158/0008-5472.CAN-25-2854. Online ahead of print.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) patients with diabetes mellitus (DM) exhibit poor clinical outcomes. Metabolic reprogramming of both cancer cells and immune compartments plays a crucial role in shaping the anti-tumor immune response in PDAC. DM-induced metabolic alteration may disrupt the intricate crosstalk between immune cells and tumor-associated immune factors, profoundly influencing PDAC progre
Spatial Multi-omics Analyses Reveal Diabetes Promotes Pancreatic Cancer Progression by Stimulating Cholesterol-Induced Neutrophil Extracellular Trap Formation
Cancer Res. 2026 Feb 9. doi: 10.1158/0008-5472.CAN-25-2854. Online ahead of print.
ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) patients with diabetes mellitus (DM) exhibit poor clinical outcomes. Metabolic reprogramming of both cancer cells and immune compartments plays a crucial role in shaping the anti-tumor immune response in PDAC. DM-induced metabolic alteration may disrupt the intricate crosstalk between immune cells and tumor-associated immune factors, profoundly influencing PDAC progression. Here, we performed an integrated, spatially resolved multi-omics study to investigate DM-associated, cell-specific metabolic remodeling within the PDAC tumor microenvironment. DM influenced interactions between tumor cells and immune cells, which accelerated PDAC growth in both humans and mice. PDAC patients with DM exhibited higher tumor-stage, poorer differentiation, and worse outcomes. Spatial metabolic and transcriptional profiling revealed that SREBP2-dependent cholesterol biosynthesis exacerbated PDAC progression. Increased cholesterol biosynthesis promoted neutrophil recruitment and accelerated formation of neutrophil extracellular traps (NETs) by stimulating the CXCL1-CXCR1/CXCR2 signaling axis, ultimately promoting PDAC growth. Inhibition of SREBP2, pharmacological blockade of CXCL1, or perturbation of NETs markedly reduced PDAC growth in diabetic mouse models. Together, these multi-omics analyses and follow-up mechanistic studies constitute an integrated approach that elucidates a metabolic mechanism by which diabetes promotes PDAC development by remodeling the tumor immune microenvironment and highlights a potential therapeutic strategy for PDAC with DM.
PMID:41661642 | DOI:10.1158/0008-5472.CAN-25-2854
-
cs.AI, q-bio.NC updates on arXiv.org
-
The challenge of generating and evolving real-life like synthetic test data without accessing real-world raw data -- a Systematic Review
arXiv:2602.06609v1 Announce Type: cross Abstract: Background: High-level system testing of applications that use data from e-Government services as input requires test data that is real-life-like but where the privacy of personal information is guaranteed. Applications with such strong requirement include information exchange between countries, medicine, banking, etc. This review aims to synthesize the current state-of-the-practice in this domain. Objectives: The objective of this Systematic
The challenge of generating and evolving real-life like synthetic test data without accessing real-world raw data -- a Systematic Review
-
cs.AI, q-bio.NC updates on arXiv.org
-
Yunjue Agent Tech Report: A Fully Reproducible, Zero-Start In-Situ Self-Evolving Agent System for Open-Ended Tasks
arXiv:2601.18226v2 Announce Type: replace Abstract: Conventional agent systems often struggle in open-ended environments where task distributions continuously drift and external supervision is scarce. Their reliance on static toolsets or offline training lags behind these dynamics, leaving the system's capability boundaries rigid and unknown. To address this, we propose the In-Situ Self-Evolving paradigm. This approach treats sequential task interactions as a continuous stream of experience, en
Yunjue Agent Tech Report: A Fully Reproducible, Zero-Start In-Situ Self-Evolving Agent System for Open-Ended Tasks
-
cs.AI, q-bio.NC updates on arXiv.org
-
Data-Centric Interpretability for LLM-based Multi-Agent Reinforcement Learning
arXiv:2602.05183v2 Announce Type: replace-cross Abstract: Large language models (LLMs) are increasingly trained in complex Reinforcement Learning, multi-agent environments, making it difficult to understand how behavior changes over training. Sparse Autoencoders (SAEs) have recently shown to be useful for data-centric interpretability. In this work, we analyze large-scale reinforcement learning training runs from the sophisticated environment of Full-Press Diplomacy by applying pretrained SAEs,
Data-Centric Interpretability for LLM-based Multi-Agent Reinforcement Learning
-
cs.AI, q-bio.NC updates on arXiv.org
-
Exploring AI-Augmented Sensemaking of Patient-Generated Health Data: A Mixed-Method Study with Healthcare Professionals in Cardiac Risk Reduction
arXiv:2602.05687v2 Announce Type: replace-cross Abstract: Individuals are increasingly generating substantial personal health and lifestyle data, e.g. through wearables and smartphones. While such data could transform preventative care, its integration into clinical practice is hindered by its scale, heterogeneity and the time pressure and data literacy of healthcare professionals (HCPs). We explore how large language models (LLMs) can support sensemaking of patient-generated health data (PGHD)
Exploring AI-Augmented Sensemaking of Patient-Generated Health Data: A Mixed-Method Study with Healthcare Professionals in Cardiac Risk Reduction
-
Nature Medicine
-
Reliability of LLMs as medical assistants for the general public: a randomized preregistered study
Nature Medicine, Published online: 09 February 2026; doi:10.1038/s41591-025-04074-yIn a randomized controlled study involving 1,298 participants from a general sample, performance of humans when assisted by a large language model (LLM) was sensibly inferior to that of the LLM alone when assessing ten medical scenarios leading to disease identification and recommendations for treatment.
Reliability of LLMs as medical assistants for the general public: a randomized preregistered study
Nature Medicine, Published online: 09 February 2026; doi:10.1038/s41591-025-04074-y
In a randomized controlled study involving 1,298 participants from a general sample, performance of humans when assisted by a large language model (LLM) was sensibly inferior to that of the LLM alone when assessing ten medical scenarios leading to disease identification and recommendations for treatment.